Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3365251 | 0.85 | HCRTR1 (0.48) | CYP2C19HCRTR1HCRTR2L3MBTL1HSD11B1 | |
| SCHEMBL3364311 | 0.83 | CYP2C19 (0.52) | CYP2C19HCRTR1HCRTR2KDM4EHPGD | |
| SCHEMBL3369115 | 0.83 | HCRTR1 (0.52) | CYP2C19HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL3367532 | 0.82 | HCRTR1 (0.47) | CYP2C19HCRTR1HCRTR2L3MBTL1KDM4E | |
| SCHEMBL3370569 | 0.80 | HCRTR1 (0.47) | CYP2C19HCRTR1HCRTR2L3MBTL1 | |
| SCHEMBL3370197 | 0.80 | GAA (0.47) | CYP2C19HCRTR1HCRTR2L3MBTL1HSD11B1 | |
| SCHEMBL3370192 | 0.80 | HCRTR1 (0.52) | HCRTR1HCRTR2L3MBTL1KDM4EHSD11B1 | |
| SCHEMBL3366771 | 0.79 | CPT1A (0.53) | HCRTR1HCRTR2KDM4EHPGDHSD11B1 | |
| SCHEMBL3367869 | 0.77 | HCRTR1 (0.59) | CYP2C19HCRTR1HCRTR2L3MBTL1KDM4E | |
| SCHEMBL3368254 | 0.77 | HCRTR1 (0.52) | CYP2C19HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532141-B1 | 2-PYRROLIDIN-2-YL- [1,3,4]-OXADIAZOLE DERIVATIVES AND THE USE OF THE SAME AS ANTIDEPRESSANTS | GRUENENTHAL GMBH (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7105538-B2 | 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | CYP2C19 147/4885HCRTR1 461/4885HCRTR2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.